9th National Retrovirus Conference: new treatments, new choices.
Laurence
Jeffrey
J
D016915:AIDS Vaccines / Q000276:immunology; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D015704:CD4 Antigens / Q000378:metabolism; D002986:Clinical Trials as Topic; D003497:Cyclic N-Oxides / Q000008:administration & dosage / Q000627:therapeutic use; D000077560:Enfuvirtide; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008561:Membrane Fusion; D010091:Oximes; D010349:Patient Compliance; D010446:Peptide Fragments / Q000627:therapeutic use; D010880:Piperidines; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use; D015728:Receptors, HIV / Q000378:metabolism
D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D015704:CD4 Antigens; D003497:Cyclic N-Oxides; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D010091:Oximes; D010446:Peptide Fragments; D010880:Piperidines; D011725:Pyridines; D015728:Receptors, HIV; D000077560:Enfuvirtide; C438583:Ancriviroc